• Ovid Therapeutics CFO Carter Charles Ross filed an initial Form 3 showing 44,375 common shares held plus employee stock options for 406,250 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001779359-26-000002), on July 08, 2026, and is solely responsible for the information contained therein.